

# Michele Malagola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7615713/publications.pdf>

Version: 2024-02-01

100  
papers

1,953  
citations

236612

25  
h-index

288905

40  
g-index

100  
all docs

100  
docs citations

100  
times ranked

2814  
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. <i>Haematologica</i> , 2017, 102, 865-873.	1.7	206
2	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. <i>Blood</i> , 2010, 115, 3671-3677.	0.6	151
3	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. <i>Blood</i> , 2002, 99, 443-449.	0.6	133
4	Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 1791-1795.	0.6	67
5	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	2.5	66
6	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	1.3	63
7	Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1 Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2013, 19, 3297-3308.	3.2	61
8	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 5138-5144.	0.6	49
9	First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. <i>Leukemia Research</i> , 2004, 28, 987-990.	0.4	43
10	Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2005, 131, 172-179.	1.2	43
11	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease. <i>Transplantation</i> , 2016, 100, e147-e155.	0.5	40
12	Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. <i>Annals of Hematology</i> , 2016, 95, 681-693.	0.8	39
13	Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. <i>Leukemia Research</i> , 2008, 32, 1800-1808.	0.4	36
14	Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. <i>Leukemia Research</i> , 2010, 34, 942-945.	0.4	36
15	Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. <i>American Journal of Transplantation</i> , 2021, 21, 1622-1628.	2.6	35
16	Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells). <i>PLoS ONE</i> , 2017, 12, e0172430.	1.1	35
17	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> . 2019, 25, 2388-2397.	2.0	33
18	Postremission sequential monitoring of minimal residual disease by <sc>WT</sc> 1 Q&#x2013;<sc>PCR</sc> and multiparametric flow cytometry assessment predicts relapse and may help to address risk&#x2013;adapted therapy in acute myeloid leukemia patients. <i>Cancer Medicine</i> , 2016, 5, 265-274.	1.3	32

#	ARTICLE	IF	CITATIONS
19	Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 722-728.	1.2	30
20	Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases. <i>European Journal of Haematology</i> , 2008, 81, 354-363.	1.1	29
21	Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. <i>Expert Review of Hematology</i> , 2013, 6, 475-483.	1.0	29
22	Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers. <i>Oncologist</i> , 2015, 20, 323-328.	1.9	29
23	Changes in Circulating Endothelial Cells Count Could Become a Valuable Tool in the Diagnostic Definition of Acute Graft-Versus-Host Disease. <i>Transplantation</i> , 2014, 98, 706-712.	0.5	28
24	Feasibility of tumor-derived exosome enrichment in the oncohematology leukemic model of chronic myeloid leukemia. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2133-2144.	1.8	27
25	An increased expression of PI-PLC $\gamma$ 21 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. <i>Journal of Leukocyte Biology</i> , 2015, 98, 769-780.	1.5	26
26	Rapid Detection of Flt3 Mutations in Acute Myeloid Leukemia Patients by Denaturing HPLC. <i>Clinical Chemistry</i> , 2003, 49, 1642-1650.	1.5	24
27	Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. <i>Leukemia and Lymphoma</i> , 2006, 47, 469-472.	0.6	24
28	Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 731-733.	0.6	23
29	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. <i>Current Osteoporosis Reports</i> , 2017, 15, 499-506.	1.5	23
30	Multidimensional geriatric assessment for elderly hematological patients ( $\geq 60$ years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 2224-2233.	1.3	23
31	Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2007, 136, 87-95.	1.2	20
32	Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. <i>BioMed Research International</i> , 2014, 2014, 1-5.	0.9	20
33	Low Dose Ara-C for Myelodysplastic Syndromes: is it Still a Current Therapy?. <i>Leukemia and Lymphoma</i> , 2004, 45, 1531-1538.	0.6	18
34	Zebrafish disease models in hematology: Highlights on biological and translational impact. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 620-633.	1.8	18
35	RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?. <i>Case Reports in Oncology</i> , 2021, 13, 1263-1269.	0.3	18
36	Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome. <i>Leukemia and Lymphoma</i> , 2019, 60, 3044-3050.	0.6	17

#	ARTICLE	IF	CITATIONS
37	Advances in CMV Management: A Single Center Real-Life Experience. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 534268.	1.8	16
38	Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.. <i>Haematologica</i> , 2007, 92, 1721-1722.	1.7	15
39	Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation. <i>PLoS ONE</i> , 2017, 12, e0175337.	1.1	15
40	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014, 89, 119-124.	2.0	14
41	GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 96.e1-96.e11.	0.6	13
42	Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years. <i>Leukemia and Lymphoma</i> , 2018, 59, 2700-2705.	0.6	12
43	The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era. <i>Blood Research</i> , 2018, 53, 3.	0.5	12
44	Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?. <i>Acta Haematologica</i> , 2020, 143, 509-510.	0.7	12
45	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , 2020, 20, 1140.	1.1	12
46	Chitosan-Hydrogel Polymeric Scaffold Acts as an Independent Primary Inducer of Osteogenic Differentiation in Human Mesenchymal Stromal Cells. <i>Materials</i> , 2020, 13, 3546.	1.3	12
47	Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). <i>Bone Marrow Transplantation</i> , 2021, 56, 2272-2275.	1.3	12
48	Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML). <i>Journal of Molecular Biomarkers &amp; Diagnosis</i> , 2017, 08, .	0.4	11
49	A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 535890.	2.2	10
50	Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 35.	1.0	10
51	Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1801.	1.0	10
52	BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017036.	0.5	9
53	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019048.	0.5	9
54	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTrIMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	1.3	9

#	ARTICLE	IF	CITATIONS
55	Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era. <i>Current Cancer Drug Targets</i> , 2013, 13, 755-767.	0.8	9
56	A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients. <i>Blood</i> , 2010, 116, 4848-4848.	0.6	9
57	Chemotherapy of Secondary Leukemias. <i>Leukemia and Lymphoma</i> , 2000, 37, 543-549.	0.6	8
58	Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 227-234.	2.0	8
59	Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. <i>Cells</i> , 2021, 10, 2764.	1.8	8
60	Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. <i>Blood</i> , 2008, 112, 1184-1184.	0.6	8
61	Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
62	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. <i>Leukemia and Lymphoma</i> , 2011, 52, 2329-2335.	0.6	7
63	<i>ETV6</i>: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Family Clinical Trial. <i>Case Reports in Hematology</i> , 2020, 2020, 1-7.	0.3	7
64	Single Step Multiple Genotyping by MALDI-TOF Mass Spectrometry, for Evaluation of Minor Histocompatibility Antigens in Patients Submitted to Allogeneic Stem Cell Transplantation from HLA-Matched Related and Unrelated Donor. <i>Hematology Reports</i> , 2017, 9, 7051.	0.3	6
65	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021, 56, 605-613.	1.3	6
66	Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2005, 106, 1857-1857.	0.6	6
67	Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case?. <i>Frontiers in Oncology</i> , 2020, 10, 564521.	1.3	5
68	Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?. <i>British Journal of Haematology</i> , 2020, 190, 135-136.	1.2	5
69	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. <i>Blood</i> , 2011, 118, 786-786.	0.6	5
70	How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. <i>Cells</i> , 2022, 11, 553.	1.8	5
71	Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2005, 74, 277-281.	1.1	4
72	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	2.0	4

#	ARTICLE	IF	CITATIONS
73	Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms. <i>Cells</i> , 2021, 10, 445.	1.8	4
74	Prompt Resolution of Nasal Aspergillosis with Intra-Nasal Instillation of Liposomal Amphotericin-B (Ambisome®) and Granulocyte Transfusions. <i>Leukemia and Lymphoma</i> , 2004, 45, 637-638.	0.6	3
75	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009, 114, 860-860.	0.6	3
76	Management of Invasive Infections due to a Rare Arthroconidial Yeast, <i>Saprochaete capitata</i> , in Two Patients with Acute Hematological Malignancies. <i>Vaccines</i> , 2021, 9, 1289.	2.1	3
77	FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience. <i>American Journal of Hematology</i> , 2009, 84, 690-692.	2.0	2
78	Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing. <i>Bone Marrow Transplantation</i> , 2019, 54, 159-163.	1.3	2
79	Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion. <i>Clinical Immunology</i> , 2020, 220, 108589.	1.4	2
80	PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. <i>Blood</i> , 2009, 114, 12-12.	0.6	2
81	Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2004, 151, 85-86.	1.0	1
82	Leukemia and multi-drug resistance: too many mechanisms of drug resistance or too many doctors resistant?. <i>Leukemia and Lymphoma</i> , 2009, 50, 1058-1060.	0.6	1
83	Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?. <i>Case Reports in Hematology</i> , 2019, 2019, 1-4.	0.3	1
84	Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.. <i>Blood</i> , 2008, 112, 2118-2118.	0.6	1
85	Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2009, 114, 167-167.	0.6	1
86	Targeting HRASV12C Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. <i>Blood</i> , 2012, 120, 4676-4676.	0.6	1
87	Editorial: Strengths and Challenges of Allo-SCT in the Modern Era. <i>Frontiers in Oncology</i> , 2022, 12, 850403.	1.3	1
88	Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. <i>Blood</i> , 2008, 112, 4288-4288.	0.6	0
89	Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial. <i>Blood</i> , 2008, 112, 3998-3998.	0.6	0
90	Complete Haematological Response after Low Dose Rituximab in a Patient with Refractory Warm-Type Autoimmune Haemolytic Anaemia. <i>Blood</i> , 2008, 112, 5376-5376.	0.6	0

#	ARTICLE	IF	CITATIONS
91	RIC Allogeneic Transplantation Improves the Overall and Progression-Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLA Typing and Donor Availability. <i>Blood</i> , 2008, 112, 460-460.	0.6	0
92	Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients. <i>Blood</i> , 2009, 114, 4147-4147.	0.6	0
93	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, ClinicalTrials.Gov NCT 00858806. <i>Blood</i> , 2010, 116, 3412-3412.	0.6	0
94	Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 4924-4924.	0.6	0
95	Establishing a New Zebrafish Model to Study Malignant Transformation in Myeloproliferative Disorders. <i>Blood</i> , 2011, 118, 4711-4711.	0.6	0
96	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. <i>Blood</i> , 2011, 118, 1682-1682.	0.6	0
97	Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement. <i>Blood</i> , 2011, 118, 575-575.	0.6	0
98	Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. <i>Blood</i> , 2011, 118, 4071-4071.	0.6	0
99	SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacididine Therapy in MDS and AML Patients. <i>Blood</i> , 2014, 124, 1030-1030.	0.6	0
100	Patterns of Lymphocyte Subsets and Index of Bone Marrow Output (KRECs) Correlate Differently with Graft-Versus-Host Disease and Relapse. <i>Blood</i> , 2014, 124, 3933-3933.	0.6	0